Why the study?
Does carvedilol have antiarrhythmic properties that reduce cardiac death or prevent atrial fibrillation in high-risk patients?
Does carvedilol have antiarrhythmic properties that reduce cardiac death or prevent atrial fibrillation in high-risk patients?
Carvedilol possesses multiple electrophysiologic properties beyond beta-blockade that may contribute to its antiarrhythmic efficacy in heart failure and post-myocardial infarction patients.
May support carvedilol preference in HF or post-MI patients; leaves open whether ion channel effects improve outcomes versus other beta-blockers.
The cardiovascular drug carvedilol is characterized by multiple pharmacological actions, which translate into a wide-spectrum therapeutic potential. Its major molecular targets are membrane adrenoceptors, ion channels, and reactive oxygen species. Carvedilol's favorable hemodynamic effects are due to the fact that the drug competitively blocks beta(1)-, beta(2)-, and alpha(1)- adrenoceptors. Several additional properties have been documented and may be clinically important, including antioxidant, antiproliferative/antiatherogenic, anti-ischemic, and antihypertrophic effects. The antiarrhythmic action of carvedilol may be related to a combination of its beta-blocking effects with its modulating effects on a variety of ion channels and currents. Several studies suggest that the drug may be useful in reducing cardiac death in high-risk patients with prior myocardial infarction and/or heart failure, as well as for primary and secondary prevention of atrial fibrillation. This article will review experimental data available on the electrophysiologic properties of carvedilol, with a focus on their clinical relevance.
No takes yet. Share an insight, caveat, or question.
El‐Sherif et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: